Health Affairs January 31, 2018
In January 2017, uncertainty over consequences of the 2016 election consumed the biomedical research and development (R&D) ecosystem. One year later, much uncertainty remains, although early anxiety has been calmed somewhat by steady leadership at the National Institutes of Health (NIH) and the Food and Drug Administration (FDA). To be sure, there is still ambiguity in the R&D field around many issues, such as concern about future federal funding levels, the impact of possible drug price reforms and enhanced generic competition, and attitudes toward scientific inquiry. Industry nonetheless seems to be reassured by a favorable tax bill, the lack of action thus far on drug pricing, a strong stock market, and the nomination of one of its own as secretary...
Today's Sponsors
Today's Sponsor